Veeva Systems stock hits 52-week high at $291.71

Veeva Systems (NYSE:VEEV) Inc. Class A stock reached a 52-week high, peaking at $291.71, marking a significant milestone for the company. According to InvestingPro data, the company maintains excellent financial health with a "GREAT" overall score and holds more cash than debt on its balance sheet. This achievement reflects a robust year for the stock, which has seen a remarkable 55.82% increase over the past year. With a market capitalization of $47.4 billion and revenue growth of ~15%, the rise in Veeva’s stock price underscores the company’s strong performance and investor confidence, as it continues to expand its foothold in the cloud-computing solutions sector for the life sciences industry. This upward trajectory highlights Veeva’s strategic growth initiatives and its ability to capitalize on the increasing demand for innovative technological solutions in healthcare. Discover more insights about VEEV and 1,400+ other stocks with comprehensive Pro Research Reports, available exclusively on InvestingPro.

In other recent news, Veeva Systems reported notable developments impacting its business landscape. Mizuho (NYSE:MFG) analysts raised their price target for Veeva Systems to $295, maintaining an Outperform rating, following the company’s fiscal first-quarter 2026 results. The strong performance was attributed to the significant contribution of Veeva’s Crossix Solution. In a strategic move, Veeva Systems secured a commitment from Merck (NSE:PROR), marking the sixth top 20 global pharmaceutical company to transition to Veeva’s Vault platform. Additionally, Astellas announced the implementation of Veeva Vault CRM for its global commercial operations, including a specialized version for China. Furthermore, the Sarah Cannon Research Institute adopted the Veeva Clinical Platform to enhance the efficiency of oncology clinical trials across its network. Boehringer Ingelheim also standardized its customer data with Veeva solutions across more than 100 countries to improve engagement with healthcare professionals. Raymond (NSE:RYMD) James reiterated its Outperform rating on Veeva Systems, reflecting continued confidence in the company’s strategic partnerships and technological advancements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.